2-Chloro-6-fluoroquinazoline is a halogenated quinazoline derivative, serving as a versatile and crucial heterocyclic building block in organic synthesis. Its molecular structure features both chloro and fluoro substituents on the quinazoline core, which are excellent handles for further functionalization via nucleophilic aromatic substitution and cross-coupling reactions. This compound is primarily employed as a key intermediate in the pharmaceutical industry for the synthesis of various biologically active molecules. It is notably used in the development of tyrosine kinase inhibitors (TKIs), particularly those targeting the epidermal growth factor receptor (EGFR). The quinazoline scaffold is a privileged structure in medicinal chemistry, and this specific derivative is a common precursor to potent anticancer agents, such as gefitinib and erlotinib analogs, due to its ability to be efficiently elaborated into the core pharmacophore. As a bifunctionalized heterocycle, it finds extensive use in research and development for constructing complex molecular libraries. Its dual halogen atoms allow for sequential and selective derivatization, making it a valuable reagent for medicinal chemists exploring structure-activity relationships in drug discovery programs targeting kinase-related diseases.